97056 ⎘
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans; Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
DNA vaccine for use in pancreatic cancer patients
#1202FLT4 (VEGFR-3) AS A TARGET FOR TUMOR IMAGING AND ANTI-TUMOR THERAPY
#1203Harvesting micro algae
#1204Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy
#1205Recombinant bacterium and uses thereof
#1206Method of combination therapy using an anti-C-Met antibody
#1207Hemojuvelin fusion proteins and uses thereof
#1208KLOTHO BETA
#1209Methods for use of vascular endothelial growth factor antagonists
#1210BROAD SPECTRUM ERBB LIGAND BINDING MOLECULES AND METHODS FOR THEIR USE
#1211Multi-functional antibody polypeptide for cryptic epitope of epidermal growth factor receptor and T cell antigen
#1212Therapeutic agents comprising fusions of growth hormone and elastic peptides
#1213Stable liquid formulations of dimer VEGF antagonists
#1214Protein inhibitors to complement and VEGF pathways and methods of use thereof
#1215Klotho variant polypeptides
#1216Compositions comprising angiogenic factors and methods of use thereof
#1217Methods of treating liver conditions using Notch2 antagonists
#1218TGF-BETA RECEPTOR TYPE II VARIANTS AND USES THEREOF
#1219TGFB type II-type III receptor fusions
#1220Growth differentiation factor 11 (GDF-11) for treatment of diastolic heart failure
#1221Expression vector comprising a polynucleotide encoding a modified glutamine synthetase and a method for preparing a target protein employing the same
#1222Soluble IGF receptor Fc fusion proteins and uses thereof
#1223Antigen binding protein and its use as addressing product for the treatment of cancer
#1224Therapeutic use of p75NTR neurotrophin binding protein
#1225Methods for detecting FGFR3/TACC3 fusion genes
#1226Myostatin inhibitor comprising extracellular water-soluble domains of DLK1 as active ingredient
#1227Method for inhibiting euPTX3 to treat nasopharyngeal carcinoma by amino acid sequence
#1228Fusion polypeptide inhibiting VEGF-C, VEGF-D and/or angiopoietin-2, and use thereof
#1229Treatment of ocular neovascularization using anti-VEGF proteins
#1230HLA-DR BINDING PEPTIDES AND THEIR USES
#1231Anti-KDR antibodies and methods of use
#1232Cleavage inhibitors of transforming growth factor beta type I receptor and uses thereof in cancer therapy
#1233Peptides and methods and uses thereof for preventing retinal disorders
#1234VASCULAR ENDOTHELIAL CELL GROWTH FACTOR ANTAGONISTS AND USES THEREOF
#1235Multivalent fibronectin based scaffold domain proteins
#1236Method for producing high yield attenuated strains
#1237Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof
#1238Methods of treating lung cancer
#1239Growth hormone receptor antagonists
#1240Composition for improving skin conditions, containing extracellular domain of human bone morphogenetic protein receptor 1a as active ingredient
#1241Compositions and methods for the intracellular disruption of VEGF and VEGFR-2 by intraceptors
#1242Methods for increasing thermogenic adipocytes
#1243Tissue protective peptides and uses thereof
#1244Anti-cancer compositions containing WNT decoy receptor
#1245Fusion proteins comprising PDGF and VEGF binding portions and methods of using thereof
#1246WNT family-derived peptides and use thereof
#1247VEGF-binding protein for blockade of angiogenesis
#1248Epidermal growth factor receptor (EGFR) and methods of use in adenoviral-associated virus type 6 (AAV6) transduction
#1249Composition for use in detection of sFlt-14
#1250Fusion protein comprising anti-c-Met antibody and VEGF-binding fragment
#1251MET-binding agents and uses thereof
#1252KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
#1253Genetically modified mouse with an inducible gene with a mutant R206H exon 5 that has ectopic bone formation
#1254HAIR GROWTH METHODS USING FGFR3 EXTRACELLULAR DOMAINS
#1255Fibroblast Growth Factor Receptor-Like Molecules and Uses Thereof
#1256Human Notch1 decoys
#1257Anti-notch NRR antibodies and methods using same
#1258Monoclonal antibodies to EGFR, and uses therefor
#1259Viral Vectors Purification System
#1260Recombinant proteins and their therapeutic uses
#1261Methods of using ERBB2 conjugate peptides
#1262Ligands modified by circular permutation as agonists and antagonists
#1263Method of treatment of cancers characterized by ligand-dependent activating mutations in FGFR2 with FGFR1 ECD proteins
#1264Antagonists of BMP9, BMP10, ALK1 and other ALK1 ligands, and uses thereof
#1265Method for determining effectiveness of cancer treatment by assessing the presence of a KIF5B-RET chimeric gene
#1266Therapeutic agents comprising fusions of insulin and elastic peptides
#1267Targeting vector-phospholipid conjugates
#1268Methods of promoting fat loss comprising administering an ALK7 inhibitor
#1269Protein comprising truncated form of extracellular region protein of Frizzled 2, and pharmaceutical composition for treating bone diseases which comprises said protein
#1270Compositions for regulating iron homeostasis and methods of using same
#1271Modified chimeric polypeptides with improved pharmacokinetic properties
#1272Variant activin IIB receptor
#1273HER3 antibodies binding to the beta-hairpin of HER3
#1274Mutations in the epidermal growth factor receptor gene
#1275KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
#1276EGFR and C-Met fibronectin type III domain binding molecules
#1277EGFR and c-Met fibronectin type III domain binding molecules
#1278Antigen binding protein and its use as addressing product for the treatment of cancer
#1279Methods of treating disease with FGFR1 fusion proteins
#1280Antibodies against epidermal growth factor receptor (EGFR) and uses thereof
#1281KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
#1282Frizzled-binding agents and uses thereof
#1283Modulators of Plexin B2 activity
#1284Isolated nucleic acid molecule encoding a fusion protein comprising an activin receptor
#1285Isolated polynucleotide that encodes an ActRIIa-Fc fusion polypeptide
#1286FGFRI-BASED ANTAGONISTS WITH IMPROVED GLYCOSAMINOGLYCAN AFFINITY AND METHODS OF USING SAME
#1287Fusion proteins comprising an engineered knottin peptide and uses thereof
#1288Methods and systems for treating eclampsia or pre-eclampsia
#1289METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY CONDITIONS
#1290Method of treating a disease or condition characterised by aberrant epithelial cell proliferation
#1291Methods and compositions for inducing an immune response to EGFRvIII
#1292Method for treating cancer using an antibody that inhibits notch4 signaling
#1293Targeting vector-phospholipid conjugates
#1294MODIFIED SOLUBLE FGF RECEPTOR FC FUSIONS METHOD
#1295SELF COUPLING RECOMBINANT ANTIBODY FUSION PROTEINS
#1296Immunotherapy against ErbB-3 receptor
#1297Chimeric peptides comprising HER-2 B-cell epitopes and Tcell helper epitopes
#1298Designed ankyrin repeat proteins binding to platelet-derived growth factor
#1299IGFBP-3 DERIVATIVES AND USES THEREOF
#1300Fusion polypeptides comprising an active protein linked to a mucin-domain polypeptide
#1301Fusion polypeptides comprising mucin-domain polypeptide linkers
#1302Ligands modified by circular permutation as agonists and antagonists
#1303FGFR2 fusion proteins comprising C-terminal deletion mutants of FGFR2-IIIC
#1304VEGF antagonist compositions and uses thereof
#1305HER2Delta16 peptides
#1306Truncated HER2 SRM/MRM assay
#1307Monoclonal antibody that binds human notch2 and notch3
#1308Use of a VEGF antagonist to treat angiogenic eye disorders
#1309Method of promoting bone growth by an anti-actriia antibody
#1310Variant activin receptor polypeptides and uses thereof
#1311HER2 binding peptides labeled with aluminium-[18] fluoride complexed by NOTA
#1312Somatostatin receptor-based cancer therapy
#1313Notch1 receptor antibodies and methods of treatment
#1314Humanized transgenic animal
#1315VEGF-activated trail ligands
#1316EGFR-based peptides
#1317Covalently dimerized bivalent binding agents
#1318Methods and compositions for the diagnosis and treatment of cancer resistant to anaplastic lymphoma kinase (ALK) kinase inhibitors
#1319Pharmaceutical compositions comprising peptide antagonists of vascular endothelial growth factor
#1320Stabilized receptor polypeptides and uses thereof
#1321Sequential administration of a replication defective adenovirus vector in vaccination protocols
#1322ErbB interface peptidomimetics and methods of use thereof
#1323Immunogenic epitopes, peptidomimetics, and anti-peptide antibodies, and methods of their use
#1324EGFR-related polypeptides and methods of use
#1325Anti-Tie2 antibodies and uses thereof
#1326Method for the treatment of obesity
#1327FGFR-Fc fusion proteins and the use thereof
#1328Fusion protein for antagonizing angiogenesis inducible factors and uses thereof
#1329Vaccine for the prevention of the recurrence HER2/neu expressing cancer
#1330Fibronectin based scaffold proteins having improved stability
#1331Variants derived from ActRIIB
#1332High affinity binding site of HGFR and methods for identification of antagonists thereof
#1333Methods of inhibiting vascular endothelial growth factor activity
#1334PDGF receptor beta binding polypeptides
#1335Truncated ACTRIIB-FC fusion protein
#1336TARGETING COMPOUNDS
#1337POLYNUCLEOTIDES AND CONSTRUCTS ENCODING SFLT1-14 AND METHOD FOR EFFICIENT PROPAGATION AND EXPRESSION THEREOF
#1338Compositions and Methods for the Intracellular Disruption of VEGF and VEGFR-2 by Intraceptors
#1339Microvesicles derived from cell protoplast and use thereof
#1340Asthma diagnosis using the neuropilin-1 gene, and method for screening for a therapeutic agent for asthma
#1341Inhibition of AXL signaling in anti-metastatic therapy
#1342Polynucleotides encoding BMP-ALK3 antagonists
#1343Recombinant Adenovirus Having Anti-Angiogenesis Activity
#1344METHODS OF TREATING LIVER CONDITIONS USING NOTCH2 ANTAGONISTS
#1345Antagonists of ligands and uses thereof
#1346Cell Culture Compositions Capable of Producing a VEGF-Binding Fusion Polypeptide
#1347Method of identifying transmembrane protein-interacting compounds
#1348HER-2 peptides and vaccines
#1349ACTRIIB-FC polynucleotides, polypeptides, and compositions
#1350Polynucleotides encoding FGFR1-IIIc ECD fusion proteins
#1351Hair growth methods using FGFR3 extracellular domains
#1352Chimeric Receptors and Methods for Identifying Agents Exhibiting an Activity on Type 1 Single Pass Transmembrane Receptors
#1353Reduction of TGF beta signaling in myeloid cells in the treatment of cancer
#1354Compositions comprising ALK1-ECD protein
#1355Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
#1356METHODS AND COMPOSITIONS FOR MODULATING ANGIOGENESIS AND PERICYTE COMPOSITION
#1357Fusion polypeptides capable of activating receptors
#1358Epidermal growth factor receptor variants and pharmaceutical compositions thereof
#1359Fusion polypeptides capable of activating receptors
#1360Use of Follistatin-Like Related Gene (FLRG) to Increase Muscle Mass
#1361KDR peptides and vaccines comprising the same
#1362Growth hormone fusion proteins
#1363Multivalent fibronectin based scaffold domain proteins
#1364Epidermal Growth Factor Receptor (EGFR) Protein SRM Assay
#1365THERAPEUTIC AGENTS COMPRISING ELASTIC PEPTIDES
#1366FGFR extracellular domain acidic region muteins
#1367Activin-actriia antagonists and uses for treating multiple myeloma
#1368Use of cytokine receptors as biomarkers and therapeutic targets in human cancer
#1369KDR peptides and vaccines comprising the same
#1370Epidermal growth factor receptor mutations
#1371Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor
#1372INHIBITORS OF RECEPTOR TYROSINE KINASES (RTK) AND METHODS OF USE THEREOF
#1373Variant activin receptor polypeptides and uses thereof
#1374Crystal structures of neuropilin fragments and neuropilin-antibody complexes
#1375Anti-angiogenic compounds
#1376Polypeptide specifically binding to vascular endothelial growth factor, fusion protein including polypeptide, and methods therefor
#1377Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies
#1378Promiscuous HER-2/Neu CD4 T cell epitopes
#1379Use of Low Affinity Neurotrophin Receptor P75 As Marker for High Differentiation Potential Muscle Stem Cells, Muscle Satellite Cells, And Degenerative Skeletal Muscle Diseases
#1380FGFR2-IIIb fusion proteins and methods of making them
#1381Human long pentraxin 3 expression system and uses thereof
#1382Truncated epiderimal growth factor receptor (EGFRt) for transduced T cell selection
#1383Prospective Identification and Characterization of Breast Cancer Stem Cells
#1384Epitope peptides derived from vascular endothelial growth factor receptor 1 and vaccines containing these peptides
#1385NOVEL IDENTIFIED ONCOGENE WITH KINASE-DOMAIN (NOK)
#1386Methods of treatment by administering antibodies to notch receptors
#1387HER3 binding polypeptides
#1388Tissue protective peptides and uses thereof
#1389Broad spectrum ErbB ligand binding molecules and methods for preparing and using them
#1390Use of FGFR1 extra cellular domain proteins to treat cancers characterized by ligand-dependent activating mutations in FGFR2
#1391VASCULAR ENDOTHELIAL CELL GROWTH FACTOR ANTAGONISTS AND USES THEREOF
#1392FGFR1 extracellular domain combination therapies for lung cancer
#1393Method of modulating integrin mediated cellular activity and agents useful for same
#1394METHOD
#1395VEGF-RELATED PROTEIN
#1396METHODS FOR PROTECTING DOPAMINERGIC NEURONS FROM STRESS AND PROMOTING PROLIFERATION AND DIFFERENTIATION OF OLIGODENDROCYTE PROGENITORS BY NRG-2
#1397POLYPEPTIDES AND POLYNUCLEOTIDES FOR ENHANCING IMMUNE REACTIVITY TO HER-2 PROTEIN
#1398Multiepitope vaccine for Her2/neu-associated cancers
#1399Modified soluble FGF receptor Fc fusions method
#1400Inhibitors of the epidermal growth factor receptor-heat shock protein 90 binding interaction
#1401Methods of promoting fat loss comprising administering an ALK7 inhibitor
#1402Stable liquid VEGF antagonist formulations
#1403HER2 BINDERS
#1404Hemojuvelin fusion proteins and uses thereof
#1405Methods for treating a disease caused by choroidal neovascularization
#1406Methods for increasing adiponectin
#1407Methods for increasing thermogenic adipocytes
#1408Tissue protective peptides and uses thereof
#1409Cell lines that secrete anti-angiogenic antibody-scaffolds and soluble receptors and uses thereof
#1410WNT ANTAGONISTS AND THEIR USE IN THE DIAGNOSIS AND TREATMENT OF WNT-MEDIATED DISORDERS
#1411CRIPTO ANTAGONISM OF ACTIVIN AND TGF-B SIGNALING
#1412COMPOSITIONS AND METHODS FOR USING MULTISPECIFIC-BINDING PROTEINS COMPRISING AN ANTIBODY-RECEPTOR COMBINATION
#1413Pancreatic cancer targets and uses thereof
#1414Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins
#1415Method of promoting bone growth by an anti-activin A antibody
#1416High affinity binding site of HGFR and methods for identification of antagonists thereof
#1417Compositions comprising angiogenic factors and methods of use thereof
#1418Method for treating cancer or cancer metastasis
#1419Dimer VEGF antagonist formulations
#1420TRUNCATED ACTIVIN TYPE II RECEPTOR AND METHODS OF USE
#1421Extracellular allosteric inhibitor binding domain from a tyrosine kinase receptor
#1422CRIPTO ANTAGONISM OF ACTIVIN AND TGF-B SIGNALING
#1423HER-2 BINDING ANTAGONISTS
#1424VEGF antagonist formulations for intravitreal administration
#1425Sulfation of Wnt pathway proteins
#1426Cell culture compositions capable of producing a VEGF-binding fusion polypeptide
#1427Epidermal growth factor receptor (EGFR) and methods of use in adenoviral-associated virus type 6 (AAV6) transduction
#1428Method for promoting bone growth using activin-actriia antagonists
#1429ACTIVIN-ACTRII ANTAGONISTS AND USES FOR INCREASING RED BLOOD CELL LEVELS
#1430Frizzled-binding agents and their use in screening for WNT inhibitors
#1431OPTIMIZING ERYTHROPOIETIN THERAPY
#1432COMPOSITIONS AND METHODS OF TREATING TUMORS
#1433Method of treatment for lymphedema comprising administering a polynucleotide encoding VEGF-D
#1434METHODS AND COMPOSITIONS FOR THE TREATMENT AND DIAGNOSIS OF VASCULAR INFLAMMATORY DISORDERS OR ENDOTHELIAL CELL DISORDERS
#1435FZD8 extracellular domains and FZD8 extracellular domain fusion molecules and treatments using same
#1436ANTAGONISTS OF ACTRIIB AND USES FOR INCREASING RED BLOOD CELL LEVELS
#1437NOTCH1 receptor antibodies and methods of treatment
#1438WNT ANTAGONISTS AND THEIR USE IN THE DIAGNOSIS AND TREATMENT OF WNT-MEDIATED DISORDERS
#1439PROSAPOSIN AS A NEUROTROPHIC FACTOR
#1440NOVEL INHIBITORS OF VASCULAR ENDOTHELIAL GROWTH FACTOR ACTIVITY, THEIR USES AND PROCESSES FOR THEIR PRODUCTION
#1441NOVEL INHIBITORS OF VASCULAR ENDOTHELIAL GROWTH FACTOR ACTIVITY, THEIR USES AND PROCESSES FOR THEIR PRODUCTION
#1442Inhibitors of vascular endothelial growth factor activity
#1443NOVEL INHIBITORS OF VASCULAR ENDOTHELIAL GROWTH FACTOR ACTIVITY, THEIR USES AND PROCESSES FOR THEIR PRODUCTION
#1444Compositions and methods for producing inhibitors of vascular endothelial growth factor activity
#1445Antibodies specific for sulfated sclerostin
#1446Sulfonated sclerostin, antibodies, epitopes and methods for identification and use therefor
#1447Isolated protein comprising an activin type IIB5 receptor polypeptide and uses thereof
#1448ECD carboxy-terminal deletion FGFR4 fusion proteins and methods of producing them
#1449ERYTHROPOIETIN
#1450Inhibitors of TGF-R signaling for treatment of CNS disorders
#1451VEGF antagonist formulations for intravitreal administration
#1452METHODS TO IDENTIFY MACROMOLECULE BINDING AND AGGREGATION PRONE REGIONS IN PROTEINS AND USES THEREFOR
#1453Methods and compositions for the diagnosis and treatment of cancer resistant to anaplastic lymphoma kinase (ALK) kinase inhibitors
#1454Use of cytokine receptors as biomarkers and therapeutic targets in human cancer
#1455Plasmids coding for p185protein sequence variants and therapeutic uses thereof
#1456Epitope peptides derived from vascular endothelial growth factor receptor 1 and vaccines containing these peptides
#1457ActRIIB FUSION POLYPEPTIDES AND USES THEREFOR
#1458p185-encoding DNA and therapeutical uses thereof
#1459Growth Factor Binding Constructs Materials and Methods
#1460Promiscuous HER-2/Neu CD4 T cell epitopes
#1461Antagonists of ligands and uses thereof
#1462Neuregulin antagonists and use thereof in treating cancer
#1463Methods using recombinant anti-epidermal growth factor receptor antibody compositions
#1464Human Notch3 based fusion proteins as decoy inhibitors of Notch3 signaling
#1465Activin-actriia antagonists for inhibiting germ cell maturation
#1466Methods for using inhibitors of vascular endothelial growth factor activity
#1467HARVESTING MICRO ALGAE
#1468Polypeptide specifically binding to vascular endothelial growth factor, fusion protein including polypeptide, and methods therefor
#1469PROSAPOSIN AS A NEUROTROPHIC FACTOR
#1470DETERMINATION OF RENIN-PRORENIN RECEPTOR ACTIVITY
#1471Therapy delivery and monitoring using a gene of interest-reporter fusion protein and optical imaging
#1472Isolated nucleic acid molecules encoding variant activin receptor polypeptides
#1473Fully human antibody to human TNFα, molecular evolution and use thereof
#1474RODENT CANCER MODEL FOR HUMAN FGFR4 ARG388 POLYMORPHISM
#1475TGF-Beta Antagonist Multi-Target Binding Proteins
#1476Cytotoxic T cell defined EGFR peptide and an optimized derivative peptide
#1477Fusion Polypeptides Capable of Activating Receptors
#1478EPHRIN-B RECEPTOR PROTEIN INVOLVED IN CARCINOMA
#1479Interleukin-2/soluble TGA-beta type II receptor B conjugates and methods and uses thereof
#1480Cytotoxic T-Lymphocyte-Inducing Immunogens for Prevention, Treatment and Diagnosis of Cancer
#1481TREATMENT OF PULMONARY EDEMA
#1482Crystal of egfr extracellular domain and cetuximab fab fragment, and uses thereof
#1483Shortened Alk1 regulatory fragment
#1484Targeting TGF-β as a therapy for Alzheimer's disease
#1485Human antigen binding proteins that bind β-Klotho, FGF receptors and complexes thereof
#1486Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
#1487Recombinant anti-epidermal growth factor receptor antibody compositions
#1488Recombinant Anti-Epidermal Growth Factor Receptor Antibody Compositions
#1489METHODS FOR TREATING FATTY LIVER DISEASE
#1490Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
#1491GENETICALLY ENGINEERED CELLS WHICH EXPRESS BONE MORPHOGENIC PROTEINS
#1492EphA4 Polypeptide Having a Novel Activity and Use Thereof
#1493IN VITRO METHODS FOR DETECTING RENAL CANCER
#1494KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
#1495Variants derived from ActRIIB and uses therefor
#1496Chimeric peptides comprising HER-2 B-cell epitopes and T-helper epitopes
#1497Platelet derived growth factor receptor alpha (PDGFRA) polypeptides comprising activating mutation(s)
#1498p185-encoding DNA and therapeutical uses thereof
#1499Screening and Therapy for Lymphatic Disorders Involving the FLT4 Receptor Tyrosine Kinase (VEGFR-3)
#1500INHIBITORS OF ONCOGENIC ISOFORMS AND USES THEREOF